For the Inventor, By the Inventor

Enter assignee name

Pharnext

USPTO Granted Patents = 54

CIPO Patents = 67

EPO Patents = 36

Trademarks = 6

Forward Citations = 206

Loading Chart...

Loading Chart...

21 inventors (with patents filed for the assignee):

Daniel Cohen (54 out of 65 patents)

Ilya Chumakov (52 out of 85 patents)

Serguei Nabirochkin (52 out of 52 patents)

4. Rodolphe Hajj (16 out of 16 patents)

5. Oxana Guerassimenko (12 out of 13 patents)

6. Emmanuel Vial (8 out of 14 patents)

7. Mickael Guedj (6 out of 6 patents)

8. Aude Milet (3 out of 3 patents)

9. Klaus-Armin Nave (3 out of 7 patents)

10. Thomas Prukop (3 out of 3 patents)

11. Michael Sereda (3 out of 3 patents)

12. Esther Graudens (2 out of 2 patents)

13. Nathalie Cholet (2 out of 2 patents)

14. Viviane Bertrand (2 out of 2 patents)

15. Mickaël Guedj (2 out of 2 patents)

Core Competencies:

CMT Disease

Alzheimer Disease

Neurological Disorders

Amyotrophic Lateral Sclerosis

Parkinson's Disease

Diabetes Treatment

Nootropic Compositions

Angiogenesis Modulation

Synapse Function

Combinatorial Therapies

Biomarker Detection

Stable Oral Solutions

54 patents: Sort by Forward Citations

1. 12226413 - Early treatment of CMT disease (2025-02-18),

2. 11672796 - Compositions for treating CMT and related disorders (2023-06-13),

3. 11576908 - Compositions for treating CMT and related disorders (2023-02-14),

4. 11291670 - Therapeutic approaches for treating Alzheimer disease and related disorders through a modulation of angiogenesis (2022-04-05),

5. 10940147 - Early treatment of CMT disease (2021-03-09),

6. 10905686 - Compositions for treating CMT and related disorders (2021-02-02),

7. 10905672 - Combination of baclofen, acamprosate and medium chain triglycerides for the treatment of neurological disorders (2021-02-02),

8. 10874644 - Therapeutic approaches for treating Alzheimer disease and related disorders through a modulation of synapse function (2020-12-29),

9. 10849851 - Stable oral solutions for combined API (2020-12-01),

10. 10799499 - Combinatorial therapies of neurological disorders (2020-10-13),

11. 10736876 - Idalopirdine-based combinatorial therapies of Alzheimer's disease (2020-08-11),

12. 10682342 - Compositions for treating amyotrophic lateral sclerosis (2020-06-16),

13. 10617689 - Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level (2020-04-14),

14. 10596160 - Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level (2020-03-24),

15. 10583135 - Compositions for treating CMT and related disorders (2020-03-10),

Pharnext is an advanced clinical-stage biopharmaceutical company pioneering new approaches to develop innovative drug combinations that target serious orphan and common neurodegenerative diseases. The company's disruptive NextCure platform simultaneously identifies and develops multiple synergistic drug combinations, called Pleodrugs, with the potential to offer improved efficacy and safety profiles. Pharnext's lead Pleodrug, PXT3003, is currently in late-stage clinical development for the treatment of Charcot-Marie-Tooth disease type 1A (CMT1A), a rare genetic neurological disorder. The company is dedicated to transforming the treatment of neurodegenerative diseases by delivering innovative therapeutic solutions to patients with unmet medical needs.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 9 2025

54 Patents

#107 in Paris

#431 in France

#12,735 in the World

Pharnext

Forward Citations = 206

21 inventors:

Daniel Cohen (54 out of 65 patents)

Ilya Chumakov (52 out of 85 patents)

Serguei Nabirochkin (52 out of 52 patents)

4. Rodolphe Hajj (16 out of 16 patents)

5. Oxana Guerassimenko (12 out of 13 patents)

Please report any incorrect information to support@idiyas.com

Loading…